Ascelia Pharma intends to carry out a new share issue prior to the company’s listing on Nasdaq Stockholm. The share issue is expected to provide Ascelia Pharma with a total of approximately SEK 212 million after deductions for expenses related to the transaction. The first day of trading is expected to be March 13, 2019.

Ascelia Pharma is an oncology-dedicated orphan drug development company located in Malmö, Sweden.

Vator Securities is the Sole Global Coordinator and Bookrunner in connection with the share issue and Ascelia Pharma’s financial advisor. Baker McKenzie is legal advisor to Vator Securities. Baker McKenzie’s team mainly consists of Joakim Falkner, Johanna Flink and Stefan Balazs.

Explore Our Newsroom